All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, August 19, 2022
Home » Blogs » BioWorld MedTech Perspectives » IPO flurry sparks optimism for med-tech

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech / IPO

IPO flurry sparks optimism for med-tech

July 6, 2015
By Amanda Pedersen
No Comments

moneyIPOs in the United States may be lagging overall, but in med-tech we have seen a flurry of IPO activity, sparking some long overdue optimism regarding the health of the industry.

Most recently, Natera, a California-based company, began trading (NASDAQ: NTRA) this past Thursday at $22.10 after pricing 10 million shares of its common stock at $18, the high end of the expected $17 to $18 range. Natera is a genetic testing company that develops non-invasive methods for analyzing DNA.

ConforMIS, a Massachusetts-based company, also received a warm welcome from investors when it began trading last Wednesday (NASDAQ: CFMS) at $18, after pricing its IPO of 9 million shares of common stock at $15 a share, the middle of the expected $14 to $16 range. Shares jumped to a high of $20.42 (a 36% increase over the IPO price) and closed Wednesday at $19.25. ConforMIS has developed a platform technology for making customized joint replacement implants that are individually sized and shaped to fit each patient’s anatomy, based on CT scans.

Other companies that have either gone public already this year or have reported plans to go public include Virginia-based Evolent Health, California-based Glaukos, Maryland-based OpGen, Massachusetts-based Infraredx and RainDance Technologies, California-based Avinger and Invitae,

The interest in the public markets has not been limited to the U.S. either. California-based AirXpanders has set its sights on an IPO in Australia, seeking to raise AU $36.5 million with plans to list on the Australian Securities Exchange. Also, Paris-based Labco reported plans to launch a €545 million ($598 million) IPO in Europe.

Interestingly, not all industries have enjoyed the same trend this year. CohnReznick, an accounting, tax, and advisory firm serving the middle market, reported a drop in IPOs during the first half of 2015. The firm found that 109 IPOs were launched in the first half of the year, a 32% decline compared to the first half of 2014. The firm said activity in the healthcare and life sciences sectors was consistent, however, and represented 43% of all middle market IPO activity compared to 38% in the second quarter 2014.

Time will tell what the current IPO window will mean for the medical device industry as a whole and how long it will last, but it is certainly a welcome trend over the IPO draught that we’ve been used to.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Aug. 19, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Aug. 19, 2022.
  • Pig organ cells

    Whole body cellular function recovery in pigs after death

    Science
    A new system for restoring cell function and tissues in mammals after death could expand the availability of organs for transplantation. The research also opens...
  • TPOXX

    Siga leads monkeypox antiviral research, amid lack of interest from big pharma

    BioWorld
    After declarations from the World Health Organization and the U.S. government that monkeypox is a public health emergency, attention is turning to the pharma...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing